Previous studies which involved Eastern Asia populations showed KRAS mutation was associated with worse prognosis in stage III or high-risk stage II colon cancer patients10, while lack of significant association between BRAF mutation and DFS was in accordance with our results and other clinical trial researches based on western populations11, 12, 33. This evidence concerns the gene KRAS and malignant colon neoplasm.